Anaemia: Approach to diagnosis by Alli, N et al.
23       January 2017, Vol. 107, No. 1
CME
Red cells are produced in the bone marrow (BM) from myeloid 
progenitor cells, where their production requires a permissive BM 
micro-environment and adequate substrate (including iron, vitamin 
B12 and folate) for Hb, protein and DNA synthesis. Erythropoiesis is 
controlled by erythropoietin (EPO), which is synthesised by peri-
tubular fibroblasts in the renal cortex in response to reduced oxygen 
tension. 
According to the World Health Organization (WHO), anaemia is 
defined as ‘a condition in which the number of red blood cells or their 
oxygen-carrying capacity is insufficient to meet physiologic needs’. It 
is the most common disorder globally and one of the conditions that 
general practitioners most frequently encounter. Anaemia is rarely an 
isolated disease and is most often a sign of an acquired or inherited 
disorder.[1]
According to the WHO global database,[2] anaemia is estimated 
to affect 1.6 billion people. The highest prevalence is found in 
preschool-age children (47.4%), followed by pregnant females 
(41.8%), non-pregnant females (30.2%), school-age children (25.4%), 
and males (12.7%).[2]
When investigating patients with anaemia, two fundamental ques-
tions have to be considered: (i) What is the cause of the anaemia?; 
and (ii) What is the urgency for correcting the anaemia, i.e. is a blood 
transfusion or other urgent intervention indicated?
Classification 
Anaemia may be classified as follows:
Based on red cell characteristics (red cell size, chromia and 
morphology):
• hypochromic microcytic
• macrocytic normochromic
• normochromic normocytic
• morphology:
• leuco-erythroblastic
• micro-/macroangiopathic.
Based on underlying mechanism:
• decreased BM production/output:
• BM aplasia/infiltrate
• ineffective haematopoiesis, e.g. megaloblastic anaemia (MA), 
myelodysplastic syndromes (MDSs), HIV
• substrate deficiency
• EPO insufficiency 
• peripheral loss/destruction:
• bleeding
• sequestration
• haemolysis.
In this issue of CME, the focus is on anaemia resulting from 
decreased BM output. Anaemia caused by peripheral loss will be 
discussed in the next issue.
Diagnostic approach to a patient with 
suspected anaemia
As anaemia may manifest in a wide range of disorders, a streamlined 
diagnostic approach is vital (Fig. 1). The approach outlined here is 
based on the abovementioned classification, clinical scenario and full 
blood count (FBC) findings.[3]
Patients generally present with symptoms of anaemia, 
i.e. increased tiredness/fatigue, dyspnoea and decreased effort 
tolerance. The seve rity of symptoms depends on the degree of 
anaemia and rate of Hb decrease. Therefore, at a given Hb level, 
anaemia from acute blood loss is likely to manifest more severely 
than anaemia of insidious onset (weeks to months). Symptoms 
during early childhood should remind one of possible inherited 
forms of anaemia, e.g. thalassaemia.
History
A detailed history is of paramount importance and often eliminates 
much of the speculation during investigation. This should include:
• interrogation of the presenting complaint and duration of the problem
• transfusion history
• dietary history, including pica (craving for unusual food items, 
generally associated with iron deficiency)
• travel history (to endemic malarial or other infectious areas)
• change in bowel habits
• bleeding (e.g. gastrointestinal and genito-urinary)
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• drug history (e.g. anticoagulants, antiplatelet 
agents, renotoxic agents, anticonvulsants)
• chronic disease (e.g. HIV, tuberculosis (TB))
• surgery (e.g. gastrectomy, small-bowel 
surgery)
• current or recent pregnancy
• family history (particularly in children).
Clinical examination
A wide range of signs and symptoms may 
be apparent. Systematic examination directs 
further investigation and may reveal the 
possible cause. 
• Skin and mucous membrane: 
• pallor is the cardinal clinical sign for 
anaemia, which should be confirmed 
by measuring the Hb level 
• angular stomatitis 
• glossitis in nutritional deficiencies
• koilonychia (spoon-shaped nails) in 
iron deficiency
• premature greying, which often accom-
panies MA
• scleral ictus, which indicates possible 
haemolysis or ineffective erythropoiesis. 
• Neuromuscular: 
• muscle weakness
• headache, lack of concentration, drow-
siness, tinnitus
• paraesthesias, peripheral neuropathy, 
ataxia and loss of vibration sense, and 
proprioception in pernicious anaemia.
• Cardiovascular:
• hyperdynamic circulation with haemic 
‘flow’ murmurs
• cardiac failure.
• Clues for infection, malignancy (e.g. lym-
phoma, leukaemia, metastatic carcinoma):
• hepatosplenomegaly
• lymphadenopathy
• bleeding manifestations (petechiae, 
purpura, ecchymosis), BM failure.
Laboratory testing
An FBC, differential and reticulocyte counts 
together with micro scopic blood smear 
examination should be the starting point 
of investigations. These confirm the clini-
cal suspicion of anaemia and direct further 
investigation. Local laboratory/population 
reference ranges that are age and gender spe-
cific should be used. The normal reference 
ranges for Hb in adults in the Witwatersrand 
area, Johannesburg, South Africa (SA) are 
as follows:[4] 
• male: 13.8 - 17.9 g/dL (anaemia <13 g/dL)
• female: 12.4 - 15.5 g/dL (anaemia <12 g/dL; 
pregnancy <11 g/dL).
A reticulocyte count gives an indication 
of the BM status, i.e. decreased activity 
v. appropriate response to the anaemia. A 
reticulocyte production index (RPI) pro-
vides a more accurate representation of mar-
row activity than an isolated reticulocyte 
count, as it corrects for the degree of anae-
mia and presence of immature reticulocytes 
in the peripheral blood. The RPI is calcu-
lated as follows:
Anaemia
FBC and 
dierential count
Reticulocyte count Blood smear microscopy
See Table 1 for 
guidance
Haemolysis
Serum haptoglobin  
level suggests haemolysis
  Indirect serum 
bilirubin   
EVH
Haemosiderinuria/
haemoglobinuria   
IVH
Normal/   MCV
Blood smear morphology 
• Oval macrocytes     serum vitamin B12 and folate
• Target cells     LFT, TFT, cholesterol
HypersplenismBleeding
Increased 
count
Decreased 
count
BM failure/inltration
Nutritional 
deciency
BM aspirate 
and trephine 
biopsy
Normal Fe studies
• Hb electrophoresis
   MCV
• Serum Fe studies and ferritin
Fe deciency
• Fe treatment
• Exclude bleeding
Normal vitamin 
B12 and folate
• BM examination
  vitamin B12/folate
• Supplementation
• Investigate cause
Family history
If chronic haemolysis, check
• Serum folate
• Serum ferritin
Locate source 
of blood loss
Investigate 
cause of
splenomegaly
Fig. 1. Algorithm depicting diagnostic approach to anaemia. (TFT = thyroid function test; LFT = liver function test; MCV = mean cell volume; 
IVH = intravascular haemolysis; EVH = extravascular haemolysis; FBC = full blood count; Fe = iron.)
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•  % reticulocytes × patient haematocrit/45 ÷ reticulocyte maturation 
time (days) in peripheral blood
The reticulocyte maturation time is calculated as follows: 
•  haematocrit >40% = 1 day, 30 - 40% = 1.5 days, 20 - 30% = 2 days, 
<20% = 2.5 days
A decreased RPI signifies a suboptimal BM response for correction 
of the anaemia. Clues for further investigation are derived from red 
cell indices (Fig. 1) and peripheral blood smear microscopy (Table 1). 
BM examination is appropriate if pathology is suspected, e.g. BM 
infiltration, BM failure, and myelodysplasia. BM aspirate smears per-
mit morphological assessment in cellular detail, but the architecture 
is disrupted, whereas in trephine biopsy sections the architecture 
is preserved, which makes it possible to detect pathology, such as 
granulomata and fibrosis.
More specialised tests are performed in individuals suspected of 
having rarer conditions that cause anaemia.
Important causes of anaemia due to 
inadequate BM output
Causes of red cell production failure include EPO deficiency (usually 
secondary to chronic kidney disease), substrate deficiency, ineffective 
erythropoiesis, BM aplasia/hypoplasia and BM displacement (malig-
nancy/fibrosis), all of which are characterised by a low RPI. 
BM aplasia/hypoplasia (primary BM 
failure)
BM failure may be inherited or acquired. In SA, the majority of 
patients have acquired idiopathic aplastic anaemia (AA). Inherited 
BM failure syndromes generally manifest in childhood and represent 
<10% of patients with AA. 
Patients may present with one or more of the following: (i) symptoms 
of anaemia; (ii) infection (due to leucopenia/neutropenia); and 
(iii) mucocutaneous bleeding (due to thrombocytopenia). The 
FBC shows a pancytopenia of varying degrees (depending on the 
seve rity), reticulocytopenia with a low RPI, and reversal of the 
normal neutrophil:lymphocyte ratio. The diagnosis is confirmed on 
microscopic BM examination.
Numerous secondary causes and associations have been identified 
in AA, but in 60 - 70% of cases the cause remains unknown. It has 
been proposed that a triggering event, such as a virus or drug, leads 
to an immune response and to inappropriate expansion of cytotoxic 
T cells that destroy haematopoietic cells. Causes include viruses (e.g. 
hepatitis virus, HIV, Epstein-Barr virus, cytomegalovirus); autoim-
mune disorders (e.g. systemic lupus erythematosis, eosinophilic 
fasciitis, Sjögren’s syndrome); drugs (a wide range, including sulfon-
amides, anticonvulsants, antimalarials; chemicals (e.g. benzene); and 
environmental factors (e.g. agricultural pesticides and radiation). The 
idiopathic variety is the largest group. Paroxysmal nocturnal haemo-
globinuria (PNH), caused by expansion of a clone with mutation of 
the glycosylphosphatidyl-inositol gene, manifests with the clinical 
triad of haemolysis, thrombosis and BM failure. PNH clones can be 
detected on flow cytometry.
Some inherited disorders are characterised by BM hypoplasia/
aplasia (affecting one or more haematopoietic cell lines), and are 
usually accompanied by one or more somatic abnormalities, i.e. 
part of a clinical syndrome. Inherited BM failure syndromes may be 
present at birth or develop later in childhood. Of these, the syndromes 
that affect all three cell lines include Fanconi anaemia, Schwachman-
Diamond syndrome and dyskeratosis congenita. Further discussion 
of these syndromes is beyond the scope of this edition of CME.
Pure red cell aplasia is characterised by an isolated, often severe 
anaemia with a marked reticulocytopenia. It may be congenital 
Table 1. Red cell morphological characteristics
Morphological observation Significance Further tests indicated and expected result
Oval macrocytes, teardrops, 
basophilic stippling, right shift
MA Serum vitamin B12 and folate levels
Hypochromia 
Microcytosis
Iron deficiency anaemia (also see pencil cells)      
Chronic disorder; thalassaemia trait
Serum ferririn, transferrin and iron levels 
Hb electrophoresis/HPLC
Sickle cells Seen in sickle cell disease Hb electrophoresis to confirm presence of Hb S, 
and quantitate Hb F level
Spherocytes Noted in hereditary spherocytosis, warm AIHA Coombs test: positive for IgG in warm AIHA
Red cell membrane analysis: selected membrane 
protein abnormalities
Elliptocytes/ovalocytes Hereditary elliptocytosis/ovalocytosis Red cell membrane analysis: selected membrane 
protein abnormalities
Autoagglutination Cold AIHA Coombs test: positive for C3d in cold AIHA
Red cell fragmentation If platelets decreased → microangiopathic 
haemolysis
If platelets normal → macroangiopathic haemolysis
Microangiopathic haemolysis: DIC screen → 
consumptive coagulopathy U&E: marked renal 
dysfunction in HUS
Altered neurological status: suspect TTP
Malaria Life-threatening infection Identify species
Monitor FBC and parasite count while on treatment
AIHA = auto-immune haemolytic anaemia; U&E = urea and electrolytes; DIC = disseminated intravascular coagulation; HUS = haemolytic uraemic syndrome; HPLC = high-performance liquid 
chromatography; TTP = thrombotic thrombocytopenic purpura.
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(Diamond Blackfan syndrome) or acquired (including viral 
infections, lymphoproliferative disorders, autoimmune disorders or 
drugs). In SA, parvovirus B19 infection in HIV-positive individuals 
is the most common cause of pure red cell aplasia. BM examination 
reveals the absence or maturation block of erythroid progenitors.
Patients with BM failure should be referred to a specialist 
haematology/oncology unit for further work-up and management. 
BM displacement by malignancy or 
fibrosis 
The presence of a leuco-erythroblastic reaction and teardrop poi-
kilocytosis on peripheral blood smear microscopy should lead one to 
suspect possible BM infiltration. 
Leukaemia and lymphoma can be further characterised on flow 
cytometry, cytogenetic analysis and polymerase chain reaction 
testing on a bone marrow aspirate sample. Immunohistochemical 
stains are also available to identify subtypes and cell types on BM 
trephine biopsy sections.
Ineffective haematopoiesis 
In ineffective haematopoiesis, the BM activity ranges from normal 
to increased, but cells die before or shortly after release into the 
circulation. Common causes for ineffective haematopoiesis include 
MA (discussed below), drugs that interrupt DNA synthesis or folate 
metabolism (e.g. methotrexate, trimethoprim, phenytoin), HIV 
infection, and the MDSs. The MDSs are clonal haematopoietic 
disorders characterised by peripheral blood cytopenias and dysplastic 
haematopoiesis, with a predisposition towards developing acute 
leukaemia. 
When suspected, MA should be excluded by means of serum 
vitamin B12 and folate levels (performed prior to blood transfusion), 
as should HIV and other chronic infections.Where no other cause for 
ineffective haematopoiesis is found, further work-up for MDSs may 
be necessary (including BM examination with cytogenetic analysis), 
particularly in older patients. 
Substrate deficiency
Iron deficiency is the most common cause of anaemia, occurring 
in an estimated 15% of the world’s population.[5] The causes of iron 
deficiency can be broadly classified as inadequate iron intake (e.g. 
nutritional deficiency, iron malabsorption) or excessive iron loss 
(mostly due to bleeding). It is most common in young children and 
women of childbearing age because of the increased iron demands 
related to rapid growth and menstrual blood losses/pregnancy, 
respectively. 
Iron deficiency causes a microcytic and/or hypochromic anae-
mia. Serum iron studies show low serum ferritin and raised 
transferrin (TF) levels, and low TF percentage saturation. The 
differential diagnosis for microcytic anaemia includes anaemia 
of chronic disorder (ACD), thalassaemia trait and sideroblastic 
anaemia. The frequency of these differential diagnoses depends on 
the demographics of the population served, with thalassaemia trait 
being common in patients of Indian or Mediterranean ancestry, and 
ACD occurring frequently in patients with chronic infection (e.g. 
HIV or TB), malignancy or autoimmune disorders. ACD is caused 
by a combination of functional iron deficiency (due to reticulo-
endothelial iron blockade), and EPO deficiency or resistance, and 
is characterised on iron studies by raised ferritin and low TF levels 
with low or normal TF percentage saturation. The anaemia is 
usually normocytic and normochromic, but can be microcytic in 
approximately one-third of cases due to long-standing iron restric-
tion at the macrophage level. 
Occasionally, the distinction between iron deficiency anaemia (IDA) 
and ACD can be blurred, as ferritin is an acute-phase protein and 
may be falsely normal or raised in patients with iron deficiency in 
the presence of acute inflammation. In this setting, the gold standard 
for discriminating IDA from ACD is evaluating BM iron stores 
microscopically. Measuring the soluble TF receptor (STFR) levels and 
calculating the STFR index (STFR:log ferritin ratio) is also of use in 
this regard, where a ratio >2 suggests iron deficiency with coexisting 
ACD.[6] Unfortunately, STFR testing is not universally available in 
SA laboratories. Of note is that serum iron levels are of minimal use 
in assessing iron stores, reflecting recent iron intake as opposed to 
overall iron status. IDA should therefore not be diagnosed solely on 
the basis of a low serum iron level. 
To establish if someone has iron deficiency, one has to include 
a thorough dietary history, with emphasis on the frequency of red 
meat consumption, excessive dietary phytates (present in grains and 
legumes) or tannins (present in tea), which inhibit iron absorption, 
and pica. In the absence of an obvious nutritional cause, a source of 
bleeding should be sought (e.g. urogenital, gastrointestinal), particu-
larly in men and postmenopausal women. 
Oral iron supplementation is the mainstay of therapy for IDA, 
but intravenous iron is occasionally necessary when more rapid cor-
rection of the Hb level is desired, if iron malabsoprtion is the main 
cause for the IDA, or if oral iron is not tolerated. A blood transfusion 
is indicated for severe, symptomatic anaemia, especially in patients 
who are bleeding. Treatment of IDA should aim at restoring the Hb 
to normal, followed by a further 4 - 6 months of therapy to replen-
ish iron stores (Table 2). Iron should ideally be given between meals 
together with vitamin C to maximise absorption, but it can be admin-
istered with food or at reduced doses in patients who experience 
excessive abdominal side-effects (e.g. abdominal discomfort, nausea 
or constipation). For patients who are refractory to oral iron therapy, 
iron malabsorption, ongoing blood loss and non-compliance should 
be considered.
The treatment of ACD is centred on management of the underlying 
cause. There may be a role for EPO supplementation, particularly in 
patients with underlying malignancy[7] and HIV.[8] Intravenous iron 
may additionally benefit patients with functional iron deficiency.[9]
MA is the other major nutritional anaemia caused by vitamin B12 
or folate deficiency. As both are required for purine biosynthesis, a 
deficiency of either nutrient hampers normal DNA synthesis, which 
results in ineffective haematopoiesis. 
Vitamin B12 deficiency is the most frequent cause of MA seen 
in general practice, the most common cause being pernicious 
Table 2. Suggested therapeutic protocols for nutritional anaemia
Micronutrient deficiency Suggested therapeutic protocol
Iron Ferrous sulphate 200 mg orally 
3 times daily between meals 
together with vitamin C for 
4 - 6 months
Folate 5 mg orally daily for 2 - 
4 months (or while the 
underlying risk factor persists)
Vitamin B12 1 000 µg daily intramuscularly 
for 5 - 7 days, followed by 
1 000 µg intramuscularly 
weekly for a month, and then 
1 000 µg intramuscularly every 
2 months for life
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anaemia. The latter leads to impaired vitamin B12 absorption owing 
to immune-mediated destruction of the gastric parietal cells and 
consequent intrinsic factor deficiency. In contrast, dietary deficiency 
and the postpartum phase most commonly cause folate depletion. 
Dietary deficiency is currently relatively uncommon in SA owing to 
mandatory fortification of maize meal and wheat flour. Other causes 
of vitamin B12 and folate deficiency are summarised in Table 3. 
MA is diagnosed by demonstrating low serum levels of vitamin B12 
or folate, along with characteristic peripheral blood smear morphology 
(including macro-ovalocytosis, teardrops, varying numbers of red cell 
fragments and basophilic stippling, and hypersegmentation (right 
shift) of neutrophils). Importantly, MA is not universally macrocytic, 
and cannot be excluded solely owing to the presence of a normal or 
even a low mean cell volume. When MA is strongly suspected, a trial 
of vitamin B12 and folate supplementation is advisable, particularly if 
levels are borderline low. 
When vitamin B12 deficiency is diagnosed, further investigation 
for pernicious anaemia is warranted. Intrinsic-factor antibodies 
are positive in 50 - 70% of cases.[10] In patients with pernicious 
anaemia, other organ-specific auto-immune disorders should be 
excluded (e.g. Addison’s disease and auto-immune thyroiditis). 
Vitamin B12 deficiency is treated with lifelong parenteral vitamin B12 
replacement therapy, while folate depletion is treated with oral folate 
supplementation (Table 3). Importantly, folate administration in 
patients with MA secondary to vitamin B12 deficiency may partially 
correct the anaemia, but does not address the effects of vitamin 
B12 deficiency on the central nervous system. Owing to the risk of 
neurological complications (such as subacute combined degeneration 
of the spinal cord) in patients with vitamin B12 deficiency, MA 
should not be presumptively treated with folate alone, as this may 
accelerate irreversible neurological damage. Although the mainstay 
of treatment in vitamin B12 deficiency is supplementation with 
vitamin B12, patients with very severe/life-threatening anaemia may 
benefit from a blood transfusion. Crucially, these patients should be 
transfused conservatively and cautiously (no more than 1 or 2 units 
of blood should be transfused, each unit running over ~2 - 4 hours, 
followed by 20 mg of intravenous furosemide (Lasix) after each 
unit), as aggressive transfusion practices are associated with a risk of 
sudden death in this setting.
Conclusion
There are numerous and varied causes of anaemia. Given the vastness 
of the topic, a thorough history, physical examination and systematic 
laboratory investigation are key elements towards determining the 
cause of the condition. 
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Table 3. Causes of vitamin B12 and folate deficiencies
Vitamin B12 deficiency Folate deficiency
Dietary deficiency
Ovolactovegetarians
Malabsorption
Pernicious anaemia
Ileal pathology
Crohn’s disease/ulcerative colitis
Infection, e.g. HIV, TB
Infiltration, e.g. lymphoma surgery
Gastrectomy, ileal resection
Diphyllobothrium latum (fish tapeworm)
Blind loop syndrome 
Drugs (e.g. proton pump inhibitors, metformin)
Dietary deficiency
Poor diet (e.g. alcoholics,  elderly)
Malabsorption
Inflammatory bowel disease
Coeliac disease
Short-bowel syndrome
Impaired folate metabolism*
Drugs (e.g. methotrexate, anticonvulsants, antimalarials)
Alcoholism
Hypothyroidism
Excessive folate demand
Chronic haemolytic anaemia
Pregnancy and lactation (particularly if the diet is poor)
*Serum folate levels may be normal.
